William Frazier Sells 10,000 Shares of Viemed Healthcare

William Frazier, the Chief Medical Officer at Viemed Healthcare, Inc., sold 10,000 shares of the company's stock on June 25, 2026. The shares were sold at an average price of $11.72 each, bringing the total transaction value to $117,200. This transaction was not part of a pre-planned trading program.

Insider Buying and Selling at Viemed Healthcare, Inc.

On June 25, 2026, William Frazier, the Chief Medical Officer, executed multiple transactions involving 10,000 shares. He sold shares at an average price of $11.72 and also acquired shares at a lower price of $1.81. Additionally, Timothy Smokoff sold 20,000 shares on June 24, 2026, at an average price of $11.50, while Michael Moore, the President, sold shares in March 2026 at prices ranging from $8.77 to $9.21.

Other Institutional Activity in Viemed Healthcare

Vanguard Capital Management LLC opened a new position in Viemed Healthcare, acquiring 1,303,384 shares valued at approximately $12 million. Forager Capital Management LLC increased its holdings by 40,000 shares, now owning 2,825,871 shares worth about $26 million, marking a 1.4% increase. In contrast, BlackRock, Inc. reduced its stake slightly by 3,514 shares, holding 4,622,562 shares valued at about $42.6 million. Goldman Sachs Group Inc. decreased its position by 25,399 shares, a 1.8% reduction, totaling 1,421,634 shares worth $13.1 million.

Viemed Healthcare, Inc. Stock Up 31.9%

Shares of Viemed Healthcare, trading on NasdaqCM under the ticker VMD, were near $11.63 on Saturday. The company has a market capitalization of approximately $445.9 million and a P/E ratio of 31.43. With a beta of 1.131, the stock shows moderate volatility. Over the past 52 weeks, the stock has ranged from a low of $5.93 to a high of $11.88, with a 50-day moving average of $9.89 and a 200-day moving average of $8.19. The company maintains a current ratio of 1.224 and a debt-to-equity ratio of 8.53.

Recent Earnings

Viemed Healthcare reported revenue of $286.6 million, reflecting a growth rate of 27.5%. The company achieved a net margin of 5.2% and a return on equity of 10.9%. Earnings per share were $0.37. The next earnings report is expected on August 5, 2026.

Analysts Set New Price Targets

On May 7, 2024, Lake Street reiterated its buy rating for Viemed Healthcare with a price target of $15. Analysts have set an average target price of $11 with only one analyst offering an opinion.

About Viemed Healthcare

Viemed Healthcare, Inc., headquartered in Lafayette, Louisiana, operates in the healthcare sector, specifically within the medical devices industry. The company provides home medical equipment and respiratory healthcare services in the United States. Viemed specializes in managing chronic respiratory diseases like COPD through non-invasive ventilation and related therapies. Founded in 2006, the company employs approximately 1,387 people under the leadership of CEO Casey Hoyt.

Bottom Line

William Frazier's recent sale of Viemed Healthcare shares is part of ongoing insider activity. Viemed Healthcare, with its focus on respiratory care, continues to draw attention from both insiders and institutions. Investors watch these moves closely, though it's important to remember that insider transactions are just one piece of the puzzle.